Navigation Links
Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
Date:9/11/2007

Deerfield, IL, September 11, 2007 Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke, or death among a diverse population of 16,390 patients with diabetes versus control therapy.

This new meta-analysis is consistent with the depth and breadth of ACTOS cardiovascular data: ACTOS studies, conducted over the past 10 years, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

Meta-analyses are pooled data across a number of studies. Although not definitive, they can offer insight into aspects of a compound or product that may not be readily available from individual studies. The overall effect calculated from a group of like or similar randomized trials can provide an estimate of the drugs overall effects in an expanded population.

This meta-analysis adds important information to the body of evidence regarding ACTOS and macrovascular ischemic events, and further documents the consistency of data from prospective studies, to meta-analysis, to observational studies.

Critical in this body of data is PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events), a trial of patients with type 2 diabetes who are at high risk for cardiovascular events. Results from this prospective, randomized, placebo-controlled outcomes trial - considered by scientists to be the most scientifically rigorous type of study - were reviewed by the FDA and added to the ACTOS label. These data show no increase in mortality or total macrovascular events with ACTOS. ACTOS is the only thiazolidinedione (TZD) with safety data from a cardiovascular outcomes trial in its label.

Given the strength and consistency of the ACTOS data as demonstrated by the prospective studies, meta-analysis, and observational studies, Takeda remains confident in the ACTOS safety profile regarding the risk of macrovascular ischemic events.


'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
646-935-3917
Ketchum
Source:Eurekalert

Related medicine news :

1. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
2. Substituting soymilk for lactose intolerant students n schools: a great option
3. ACTOS Linked to Several Cardiovascular Benefits
4. Lactose-Intolerant kids need to take dairy products to meet nutrient requirements
5. Actos Linked To Bone Fractures In Diabetic Women
6. Largest Ever Study of Genetics Behind Common Diseases Published
7. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
8. Findings on Dangerous Parasite, Toxoplasma Gondii Published
9. Siddha Medicine Texts to Be Published in English
10. Journal Recommends How To Improve The Performance Of Health Workers
11. Medical Journals should create awareness on Child survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, ... today that Legacy Health is expanding its use of Intrigma’s cloud-based physician scheduling ... successful initial proof of concept. The Portland, Oregon based health system conducted a ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... a special type of surgical procedure that can be used to diagnose and treat ... instruments can be inserted. These instruments include a special lighting system and lens that ...
(Date:5/3/2016)... ... , ... Finding the right way to address a patient’s condition before it worsens will ultimately ... board. , “You do the right thing, at the right time, at the right dose ... said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even if the cost of ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Dave Newberry, broker/owner ... Interim Care Center (PICC) annual fundraiser luncheon on Friday, May 20. “We have ... the smallest victims of drug abuse,” said Newberry. , PICC is a local Kent, ...
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been announced ... for five events throughout the month of May. , Uldrich is the author of ... outlets. He also frequently appears on the Science Channel’s FutureScape and Discovery Channel’s Inside ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology: